BAD HOMBURG, Germany, May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said:
"The first quarter of this year demonstrates that we are executing on our strategy as planned. Both segments expanded their respective margins compared to the prior year. Especially for Care Enablement, the first quarter was an inflection point as our transformation efforts, higher pricing and FME25 savings drove a solid margin improvement. We are also executing with speed our strategic portfolio optimization program. We have started the year with a slightly more favorable operating income phasing than planned and confirm our financial outlook for the full year 2024. We would not be here without the great work of our employees, whom I would like to thank for their hard work and dedication."
Key figures (unaudited) | |||||
Q1 2024 | Q1 2023 | Growth | Growth | ||
EUR m | EUR m | yoy | yoy, cc | ||
Revenue | 4,725 | 4,704 | 0 % | +2 % | |
on outlook base1 | 4,822 | 4,619 | +4 % | ||
Operating income | 246 | 261 | -6 % | -4 % | |
on outlook base1 | 416 | 338 | +23 % | ||
Net income2 | 71 | 86 | -18 % | -17 % | |
on outlook base1 | 198 | 146 | +35 % | ||
Basic EPS (EUR) | 0.24 | 0.29 | -18 % | -17 % | |
on outlook base1 | 0.67 | 0.50 | +35 % | ||
yoy = year-on-year, cc = at constant currency, EPS = earnings per share |
Focused execution against the strategic plan continues into 2024
Fresenius Medical Care successfully executed on its operational efficiency and turnaround plans. In the first quarter, the FME25 transformation program continued its momentum, delivering EUR 52 million additional sustainable savings while related one-time costs amounted to EUR 28 million. The Company is well on track to achieve the targeted additional sustainable savings of EUR 100 to 150 million by year end 2024, totaling to EUR 650 million by year end 2025.
Moreover, Fresenius Medical Care is executing its portfolio optimization plan to exit non-core and dilutive assets. As announced during the first quarter, the Company entered into agreements to divest its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador. Special items associated with portfolio optimization amounted to negative EUR 143 million in the first quarter. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.
After further signing the divestments of its dialysis clinic networks in Guatemala, Peru and Curacao, Fresenius Medical Care has now signed or closed the exit from all of its dialysis clinics operations in Latin America. The Company moreover closed the divestment of its dialysis clinic network in Turkiye and the Cura Day Hospitals Group, Australia, during April. All transactions that are currently signed as part of the Company's portfolio optimization plan are estimated to negatively impact Fresenius Medical Care by around EUR 250 million in the full year 2024 and will be treated as special items in operating income. The transactions listed above are expected to generate cash proceeds of around EUR 650 million upon closing.
Revenue development driven by solid organic growth
Revenue remained almost unchanged with EUR 4,725 million in the first quarter (+2% at constant currency, +5% organic). Revenue on outlook base1, i.e. at constant currency, excluding special items and the business impacts from closed divestitures during 2023, increased by 4%.
Care Delivery revenue increased by 1% (+3% at constant currency, +6% organic) and by 5% on outlook base1.
In Care Delivery U.S., revenue increased by 3% (+5% at constant currency, +6% organic) and by 6% on outlook base1. A growing value-based care business, reimbursement rate increases and a favorable payor mix had a positive impact, compensating negative exchange rate effects and the effect of closed or sold operations. In line with expectations, elevated missed treatments growth compared unfavorably to last year, in part due to adverse Q1 2024 weather events and an unusually mild 2023 flu season, capacity constraints in clinics in some metropolitan areas, and the remaining annualization effects from excess mortality, that weigh on U.S. same market treatment growth. Adjusted for the exit from less profitable acute care contracts (-0.4%), U.S. same market treatment growth came in as expected at -0.3%.
In Care Delivery International, revenue declined by 9% (-4% at constant currency, +4% organic), while they grew by 2% on outlook base1. The effect of closed or sold operations and a negative exchange rate effect were partially offset by organic growth. Same market treatment growth was positive at 1.4%.
Care Enablement revenue declined by 1% (+1% at constant currency, +2% organic), while they grew by 2% on outlook base1. Positive impacts from pricing were offset by negative exchange rate effects and negative volume growth compared to prior year, in the absence of sales of critical care products in China as part of a Covid-related government initiative in the first quarter 2023.
Within Inter-segment eliminations, revenue for products transferred between the operating segments at fair market value remained stable at negative EUR 360 million (+1% at constant currency).3
Better than expected earnings development driven by phasing of value-based care business
Operating income decreased by 6% to EUR 246 million (-4% at constant currency), resulting in a margin of 5.2% (Q1 2023: 5.5%). Operating income on outlook base1, i.e. at constant currency, excluding special items and the business impacts from closed divestitures during 2023, increased by 23% to EUR 416 million, resulting in a margin of 8.6% (Q1 2023: 7.3%).
Operating income in Care Delivery decreased by 34% (-34% at constant currency), resulting in a margin of 5.0% (Q1 2023: 7.6%). Operating income on outlook base1 increased by 25%, resulting in a margin of 9.3% (Q1 2023: 7.8%). The operating income development was driven by positive effects from pricing, the value-based care business and FME25 savings, while expected labor and inflationary cost increases impacted the earnings development.
Operating income in Care Enablement amounted to EUR 70 million (Q1 2023: EUR -24 million), resulting in a margin of 5.4% (Q1 2023: -1.9%). Operating income on outlook base1 increased by 23%, resulting in a margin of 6.0% (Q1 2023: 5.0%). The improvement compared to the previous year's quarter was mainly driven by savings from the FME25 program and improved pricing. These positive effects were partially offset by inflationary cost increases and unfavorable foreign currency transaction effects.
Operating income for Corporate amounted to EUR -14 million (Q1 2023: EUR 10 million). Operating income on outlook base1 amounted to EUR -19 million (Q1 2023: EUR -5 million), mainly due to higher costs related to certain global functions.
Net income2 decreased by 18% to EUR 71 million (-17% at constant currency). Net income on outlook base1 increased by 35%.
Basic earnings per share (EPS) decreased by 18% to EUR 0.24 (-17% at constant currency). EPS on outlook base1 increased by 35%.
Strong cash flow development
In the first quarter, Fresenius Medical Care generated EUR 127 million of operating cash flow (Q1 2023: EUR 143 million), resulting in a margin of 2.7% (Q1 2023: 3.0%). The operating cash flow development was negatively impacted by EUR 58 million resulting from a cyber incident at Change Healthcare, one of our U.S. service providers, in February.
Free cash flow4 amounted to EUR -2 million in the first quarter (Q1 2023:
EUR 2 million).
Outlook
Fresenius Medical Care confirms its outlook for fiscal 2024 and expects revenue to grow by a low- to mid-single digit percent rate compared to prior year. The Company expects operating income to grow by a mid- to high-teens percent rate compared to prior year.
The expected growth rates for 2024 are at constant currency, excluding special items as well as the business impacts from closed divestitures in 2023 and the settlement agreement with the U.S. government (Tricare) in Q4 2023. The 2023 basis for the revenue outlook is EUR 19,049 million and for the operating income outlook is EUR 1,540 million.
The Company also reconfirms its targets to achieve an operating income margin of 10% to 14% by 2025. This excludes impacts from portfolio changes.
Patients, clinics and employees
As of March 31, 2024, Fresenius Medical Care treated 324,884 patients in 3,862 dialysis clinics worldwide and had 117,128 employees (headcount) globally, compared to 119,845 employees as of December 31, 2023.
Conference call
Fresenius Medical Care will host a conference call to discuss the results of the first quarter on May 7, 2024, at 2:00 p.m. CEST / 8:00 a.m. EDT. Details will be available on the Fresenius Medical Care website in the "Investors" section. A replay will be available shortly after the call.
Please refer to our statement of earnings included at the end of this news and to the attachments as separate PDF files for a complete overview of the results of the first quarter of 2024. Our 6-K disclosure provides more details.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,862 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 325,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
1 | Revenue and operating income outlook, as referred to in the 2024 outlook, are both at constant currency, excluding special items as well as the business impact from closed divestitures in 2023 and the settlement agreement with the U. S. government (Tricare) in Q4 2023. For FY 2023 and 2024, special items include costs related to the FME25 program, the Humacyte remeasurements, the legal form conversion costs and effects from legacy portfolio optimization. For further details please see the reconciliation attached to the Press Release. |
2 | Net income attributable to shareholders of Fresenius Medical Care AG |
3 | The Company transfers products between segments at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within "Inter-segment eliminations". |
4 | Net cash provided by / used in operating activities, after capital expenditures, before acquisitions, investments, and dividends |
Statement of earnings | ||||
Three months ended March 31, | ||||
in € million, except share data, unaudited | 2024 | 2023 | Change | Change |
Revenue | 4,725 | 4,704 | 0.4 % | 2.5 % |
Revenue (outlook base)1 | 4,822 | 4,619 | 4.4 % | |
Costs of revenue | 3,551 | 3,555 | -0.1 % | 1.9 % |
Selling, general and administrative expense | 776 | 782 | -0.8 % | 0.7 % |
Research and development expense | 48 | 56 | -14.3 % | -13.9 % |
Income from equity method investees | (29) | (28) | 4.8 % | 4.8 % |
Other operating income | (113) | (117) | -3.4 % | -3.9 % |
Other operating expense | 246 | 195 | 26.2 % | 30.5 % |
Operating income | 246 | 261 | -5.7 % | -4.4 % |
Operating income (outlook base)1 | 416 | 338 | 23.0 % | |
Interest expense, net | 88 | 83 | 6.8 % | 9.1 % |
Income before taxes | 158 | 178 | -11.5 % | -10.6 % |
Income tax expense | 40 | 45 | -11.2 % | -10.8 % |
Net income | 118 | 133 | -11.6 % | -10.6 % |
Net income attributable to noncontrolling interests | 47 | 47 | -0.3 % | 0.9 % |
Net income2 | 71 | 86 | -17.8 % | -16.9 % |
Net income2 (outlook base)1 | 198 | 146 | 35.3 % | |
Weighted average number of shares | 293,413,449 | 293,413,449 | ||
Basic earnings per share | €0.24 | €0.29 | -17.8 % | -16.9 % |
Basic earnings per share (outlook base)1 | €0.67 | €0.50 | 35.3 % | |
In percent of revenue | ||||
Operating income margin | 5.2 % | 5.5 % | ||
Operating income margin (outlook base)1 | 8.6 % | 7.3 % | ||
1 Outlook base as referred to the 2024 outlook, presented at constant currency, excluding special items, business impacts from closed divestitures in 2023 and the Tricare settlement in Q4 2023. For a reconciliation please refer to the table at the end of the press release. | ||||
2 Attributable to shareholders of FME AG. | ||||
Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company´s outlook (outlook base) | ||
Three months ended March 31, | ||
in € million, unaudited | 2024 | 2023 |
Operating performance (outlook base) | ||
These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items and at constant currency. | ||
Revenue | 4,725 | 4,704 |
Divestitures1 | — | (85) |
Revenue excl. 2023 divestitures | 4,725 | 4,619 |
Currency translation effects | 97 | — |
Revenue (outlook base) | 4,822 | 4,619 |
Operating income | 246 | 261 |
FME25 Program | 28 | 26 |
Legal Form Conversion Costs | 1 | 2 |
Legacy Portfolio Optimization2 | 143 | 84 |
Humacyte Remeasurements | (15) | (19) |
Sum of special items | 157 | 93 |
Divestitures1 | — | (16) |
Sum of special items and 2023 divestitures | 157 | 77 |
Operating income excl. special items and 2023 divestitures | 403 | 338 |
Currency translation effects | 13 | — |
Operating income (outlook base) | 416 | 338 |
Net income3 | 71 | 86 |
FME25 Program | 20 | 20 |
Legal Form Conversion Costs | 1 | 1 |
Legacy Portfolio Optimization2 | 107 | 61 |
Humacyte Remeasurements | (11) | (14) |
Sum of special items | 117 | 68 |
Divestitures1 | — | (8) |
Sum of special items and 2023 divestitures | 117 | 60 |
Net income3 excl. special items and 2023 divestitures | 188 | 146 |
Currency translation effects | 10 | — |
Net income3 (outlook base) | 198 | 146 |
1 Business impacts from closed divestitures in 2023. | ||
2 2024: mainly comprise the impairment of intangible and tangible assets resulting from the measurement of assets held for sale (primarily Brazil, Colombia, Ecuador, Turkiye) as well as losses from divestitures (driven by the divestment of Chile renal dialysis operations); 2023: mainly comprise the derecognition of capitalized development costs and the impairment of intangible assets (licenses and distribution rights) as well as termination costs (including certain contractual obligation expenses) related to a dialysis cycler development program which was discontinued in the first quarter of 2023. | ||
3 Attributable to shareholders of FME AG. | ||
Media contact
Christine Peters
T +49 160 60 66 770
This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$21.97 |
| Daily Change: | -0.42 -1.88 |
| Daily Volume: | 479,594 |
| Market Cap: | US$12.890B |
March 19, 2024 January 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
